Physician profile
Smita S Shah
NPI 1063454817
$3,065.29
in general payments reported to CMS, 2019-2025
25 companies · $636 in 2025
The $636 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $465 · 2021: $369 · 2022: $305 · 2023: $506 · 2024: $239 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $680.91 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $460.49 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $364.26 | 2020-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $251.45 | 2019-2023 | Ocaliva |
| Novo Nordisk INC | $189.34 | 2021-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $158.98 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $153.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $135.88 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $109.31 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Pfizer INC. | $103.61 | 2022-2025 | |
| La Jolla Pharmaceutical Company | $97.05 | 2025 | Giapreza |
| Ironwood Pharmaceuticals, INC | $70.34 | 2019-2020 | |
| Ucb, INC. | $51.02 | 2019 | |
| Allergan, INC. | $42.48 | 2019-2020 | |
| Covidien Lp | $29.90 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $28.96 | 2021 | |
| Genzyme Corporation | $22.53 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $21.08 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $20.03 | 2024 | |
| Gilead Sciences, INC. | $19.76 | 2024 | |
| Boston Scientific Corporation | $15.20 | 2023 | Exalt Model D |
| Regeneron Healthcare Solutions, INC. | $14.57 | 2023 | Dupixent |
| Alfasigma USA, INC. | $13.00 | 2020 | |
| Endogastric Solutions, INC | $11.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.